Artixio

CDSCO Approved FDC List and Fixed-Dose Combination Updates in India

CDSCO approved fixed-dose combinations India

Searching for a single, complete list of approved fixed-dose combinations (FDCs) in India? There isn’t one. The Drugs Controller General (India) [DCG(I)] approves FDCs that fall under the applicable central new-drug framework, and CDSCO publishes the related approval records.

The historical and period-wise lists are on CDSCO’s official FDC and Subsequent New Drugs page. For recent approvals, manufacturers should also check CDSCO’s current approval records.

Below, we look at what the CDSCO-approved FDC list contains and where the latest official FDC information can be found. We also cover the regulatory requirements that matter most to manufacturers.

What Are Fixed Dose Combinations (FDCs) in India?

Picture a single tablet carrying two or more active drugs in a set ratio. That’s an FDC, though the dosage form isn’t always a tablet.

Not every FDC is treated the same way. Under the New Drugs and Clinical Trials Rules, 2019, some are classed as new drugs. One example is when two separately approved drugs are combined in a fixed ratio for the first time. Changes to an already approved combination can also bring it under the definition, whether that’s a new ratio, indication, route of administration, dosage or dosage form.

The Second Schedule sets out the different FDC situations, each with its own data requirements. What you’ll need depends on three things:

  • the combination itself
  • what’s already known about its ingredients
  • how the product is meant to be used

CDSCO FDC Approval Requirements in India

Once an FDC qualifies as a new drug, the New Drugs and Clinical Trials Rules, 2019 apply. Permission to import it, or to manufacture it for sale or distribution, has to come from the Central Licensing Authority, which reviews the application.

There’s no single evidence package that fits every FDC. Depending on the combination, the application may need:

  • pharmaceutical data
  • clinical evidence
  • pharmacokinetic or pharmacodynamic information
  • BA/BE data
  • stability information
  • other material required under the applicable provisions

Rationality matters too. CDSCO’s Subject Expert Committee guidance looks at whether the evidence submitted shows that an FDC is rational and useful. Reviewers may consider:

  • PK/PD interaction
  • dosage compatibility
  • efficacy and safety
  • the proposed doses and formulations
  • whether further evidence is needed

Where an FDC contains a new drug, the review may be done case by case, depending on the product and its proposed indication. A Subject Expert Committee may be consulted where appropriate.

Approved FDCs remain subject to post-market regulatory action. Under CDSCO’s drug recall framework, products may be recalled for quality defects, safety or efficacy concerns, serious adverse reactions, prohibition under the Drugs and Cosmetics Act, or suspension or cancellation of the applicable licence.

Latest CDSCO FDC Approval Lists and 2026 Updates

CDSCO’s List of FDC & Subsequent New Drugs Approved in India page doesn’t hold one rolling, consolidated list. Instead, it has separate FDC lists for different periods.

The latest period-specific FDC approval list covering recent approvals on that page, as of October 2026, is the list released on 7 April 2025 for November 2024 to March 2025.

For anything newer, also check the CDSCO CT Approvals database. It includes 2026 records specifically categorised as FDC. They are:

FDC entry Approval date
Gabapentin IP (as extended release) + Duloxetine Hydrochloride IP eq. to Duloxetine (as delayed release) (300mg + 20mg & 600mg + 20mg) film coated tablet 25 May 2026
Empagliflozin + Linagliptin + Metformin Hydrochloride IP (10mg + 5mg + 1000mg & 25mg + 5mg + 1000mg) (ER) film coated tablets 7 May 2026
Carboxymethylcellulose Sodium IP 5mg + Glycerin IP 10 mg + Sodium Perborate BP 0.028% w/v (As preservative) per 5ml eye drops 22 April 2026
Rizatriptan Benzoate IP eq. to Rizatriptan 10mg + Meloxicam IP 20mg uncoated orally disintegrating tablet 16 April 2026
Bisoprolol Fumarate IP + Telmisartan IP + Chlorthalidone IP (2.5mg + 20mg + 6.25mg & 5mg + 40mg + 12.5mg) uncoated tablet 13 April 2026
Atorvastatin Calcium IP eq. to Atorvastatin 10mg/20mg/40mg + Bempedoic Acid 180mg/180mg/180mg film coated tablet 24 March 2026
Dorzolamide Hydrochloride 22.26mg eq. to Dorzolamide 20mg + Brimonidine Tartrate IP 1mg per ml eye drop 19 March 2026
Telmisartan IP + Amlodipine Besilate IP eq. to Amlodipine + Bisoprolol Fumarate IP (40mg + 2.5mg + 5mg & 40mg + 5mg + 5mg) film coated bilayered tablets 19 March 2026
Amlodipine Besylate IP eq. to Amlodipine + Bisoprolol Fumarate IP (2.5mg + 2.5mg & 2.5mg + 5mg) film coated tablets 19 March 2026
Phenylephrine USP 12.4mg eq. to Phenylephrine 10.16mg + Ketorolac Tromethamine USP 4.24mg eq. to Ketorolac 2.88mg + Hydrochloric Acid NF + Sodium Hydroxide NF per ml intraocular solution 19 March 2026
Minoxidil IP 5% w/v + Finasteride IP 0.10% w/v + Latanoprost IP 0.03% w/v per ml topical solution 18 March 2026
Budesonide IP 160mcg + Glycopyrrolate IP 9mcg + Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 4.8mcg per actuation delivers inhalation aerosol 18 March 2026
Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin + Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin + Metformin Hydrochloride (as sustained release) IP (5mg + 50mg + 500mg & 5mg + 50mg + 1000mg) film coated bilayered tablets 18 March 2026
Combikit Each Strip contains: 1 Tablet of Part A: Dapagliflozin Tablet 10/10/10/10mg; 1 Tablet of Part B: Bisoprolol Fumarate Tablet 1.25/2.5/5/10mg; 2 Tablets of Part C: Sacubitril and Valsartan Tablet 100/100/200/200mg 18 March 2026
Fluticasone Furoate 50mcg + Umeclidinium Bromide eq. to Umeclidinium 31.25mcg + Vilanterol Trifenatate eq. to Vilanterol 12.5mcg MDI 18 March 2026
Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin + Glimepiride IP + Metformin Hydrochloride IP (as extended release) (10mg + 1mg + 1000mg & 10mg + 2mg + 1000mg) film coated bilayered tablets 18 March 2026
Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin + Glimepiride IP + Metformin Hydrochloride IP (as extended release) (10mg + 1mg + 1000mg & 10mg + 2mg + 1000mg) film coated tablets 10 February 2026
Bisoprolol Fumarate IP + Cilnidipine IP 10mg/10mg + Telmisartan IP 40mg/40mg (2.5mg + 10mg + 40mg & 5mg + 10mg + 40mg) film coated tablet 10 February 2026

These are the entries shown under the FDC category for 2026 in CDSCO’s CT Approvals database.

Role of Rational FDCs in Indian Healthcare

Combining medicines in one dosage form can help, but only when there’s a clear clinical reason for it. Whether a particular FDC adds value depends on the combination, its intended use, and whether it’s considered rational.

The National Formulary of India 2026 includes 42 rational FDC monographs:

  • 14 are new rational FDCs.
  • 5 are used in National Health Programmes.

The Formulary also notes that only FDCs considered rational by the National Regulatory Authority should be used, and only on a clinician’s advice.

That distinction matters. The benefits of an FDC can’t be taken for granted for every combination. A sound therapeutic rationale, and the regulatory evidence to back it, are still required.

Conclusion

CDSCO doesn’t maintain one consolidated FDC approved list that’s continuously updated with every recent approval. For consolidated, period-wise lists, the dedicated FDC page is still the main source. Newer FDC entries, however, may appear only in CDSCO’s current records.

For manufacturers, what it takes to get an FDC approved in India depends on the type of combination and the evidence the applicable framework calls for. One data package won’t fit every FDC.

Artixio supports pharmaceutical companies with CDSCO regulatory strategy, dossier preparation, product registration and market-entry requirements in India. Explore our pharmaceutical compliance consulting services in India.

FAQs

1. Where can I find the latest CDSCO-approved FDC list?

Start with CDSCO’s official website, which posts approved FDCs in period-wise lists. Those lists can lag behind, though. Some newer approvals show up first in CDSCO’s current approval records, so check both before treating an FDC as approved or not.

2. Has CDSCO published a consolidated FDC approved list for 2026?

Not on the dedicated FDC page. As of October 2026, the latest FDC-specific consolidated list there covers November 2024 to March 2025. CDSCO’s current records do, however, include individual 2026 entries categorised as FDC.

3. How long does an FDC application take with CDSCO?

For an FDC that falls under the new-drug framework for manufacture and sale or distribution, the New Drugs and Clinical Trials Rules, 2019 provide a 90-working-day period for the Central Licensing Authority to grant permission, reject the application, or communicate deficiencies. The actual process may take longer if additional information is requested or deficiencies need to be addressed.

4. Does every FDC require the same clinical trial or BA/BE data?

No. The evidence needed depends on:

  • the type of FDC
  • its ingredients
  • the proposed claim or indication
  • previous approvals
  • the information already available

Each FDC situation comes with its own requirements.

5. Can an FDC permission be suspended or cancelled?

Yes. If a manufacturer doesn’t comply with the applicable legal requirements or the conditions of permission, the Central Licensing Authority may suspend or cancel the permission, following the procedure set out in the rules.

Get in touch

×